drugset / Trial / NCT03454048

Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2

NCT03454048

RandomizedParallel-groupOpen-labelOther

Summary

This is a single-center, open label study. The primary aim of this project is to develop a controlled human malaria infection transmission model ("CHMI-trans") or "challenge model" to evaluate the capacity of vaccines, biologics (monoclonal antibodies, or mAbs), and drugs to block malaria parasite transmission by assessing infectiousness of Plasmodium falciparum (Pf) gametocyte carriers for Anopheles mosquitoes.

Timeline

Start
2018-05-07
Primary completion
2018-11-01
Completion
2018-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject piperaquine Small molecule 480 mg Oral
Subject piperaquine Small molecule 960 mg Oral
Subject pyrimethamine Small molecule 50 mg
Subject sulfadoxine Small molecule 1000 mg
Background Atovaquone Small molecule 1000 mg
Background Proguanil Small molecule 400 mg